Drug Trial Radar · NCT05956418
A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 13, 2021
Primary completion
Nov 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Pharmazz, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multi-centric, open-labeled, phase-IV clinical study to evaluate the safety and efficacy of centhaquine citrate (LYFAQUIN™), a first-in-class drug for treating hypovolemic shock, a life-threatening condition caused by severe blood or fluid loss. Centhaquine has been found to be an effective resuscitative agent in rat, rabbit, and swine models of hemorrhagic shock. It has demonstrated the ability to decrease blood lactate levels, increase mean arterial pressure, enhance cardiac output, and reduce mortality rates. The increase in cardiac output during resuscitation is primarily attributed to an augmentation in stroke volume. Centhaquine exerts its effects by acting on the venous α2B-adrenergic receptors, which enhances venous return to the heart. Additionally, it produces arterial dilation by targeting central α2A-adrenergic receptors, thereby reducing sympathetic activity and systemic vascular resistance.
Conditions
- Hypovolemic Shock
Interventions
CenthaquineDrug
Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to 7 days
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
ACSR Government Medical College and Hospital
Nellore, Andhra Pradesh, India · Recruiting
All India Institute of Medical Sciences (AIIMS)
Raipur, Chhattisgarh, India · Recruiting
Aman Hospital
Vadodara, Gujarat, India · Recruiting
New Era Hospital
Nagpur, Maharashtra, India · Recruiting
Seven Star Hospital
Nagpur, Maharashtra, India · Recruiting
Meditrina Hospital
Nagpur, Maharashtra, India · Recruiting
Sri Guru Ram Das University of Health Sciences (SGRDH)
Amritsar, Punjab, India · Recruiting
Dayanand Medical College & Hospital (DMCH)
Ludhiana, Punjab, India · Recruiting
Christian Medical College and Hospital (CMC)
Ludhiana, Punjab, India · Recruiting
Government Medical College
Kota, Rajasthan, India · Recruiting
KG Hospital
Coimbatore, Tamil Nadu, India · Recruiting
Pushpanjali Hospital
Agra, Uttar Pradesh, India · Recruiting
Maharani Laxmi Bai Medical College (MLBMC)
Jhānsi, Uttar Pradesh, India · Recruiting
Nirmal Hospital
Jhānsi, Uttar Pradesh, India · Recruiting
Ganesh Shankar Vidyarthi Memorial Medical College (GSVM)
Kanpur, Uttar Pradesh, India · Recruiting
Janta Hospital
Varanasi, Uttar Pradesh, India · Recruiting
IPGMER & SSKM Hospital
Kolkata, West Bengal, India · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.